Nearly nine thousand people, and microdosers reported lower anxiety and depression
What they did
Researchers used a mobile app to compare 4,050 people who microdose with 4,653 people who do not, across mood, anxiety and stress measures. Psilocybin accounted for 85 percent of the substances used.
What they found
Microdosers reported lower depression, anxiety and stress than non-microdosers across genders. The gap was widest among people who reported existing mental health concerns.
Worth knowing
Observational and self-selected. People who choose to microdose and then report on it are not a random sample, so this shows an association and cannot show cause. Read it alongside the controlled trials above.
Rootman et al. Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression. Scientific Reports, 2021.
Read the sourceKeep reading
microdosingSelf-blinded microdosers improved, but so did the placebo groupmicrodosingWhen people guessed right, they felt moremicrodosingTwo more controlled trials, two more null resultsThis is the part of the research that maps most closely to what we make. It is also the thinnest evidence base on the shelf, which is why we describe our capsules as a ritual rather than a remedy. See the range.
For education, not medical advice. Every write-up links back to the original source.
Nothing here is a claim that our products treat, cure or prevent any condition. Talk to a doctor before changing anything about your health.